Cargando…
Cannabinol (CBN; 30 and 300 mg) effects on sleep and next-day function in insomnia disorder (‘CUPID’ study): protocol for a randomised, double-blind, placebo-controlled, cross-over, three-arm, proof-of-concept trial
OBJECTIVE: Insomnia is the most prevalent sleep disorder, with few effective pharmacotherapies. Anecdotal reports and recent preclinical research suggest that cannabinol (CBN), a constituent of Cannabis sativa derived from delta-9-tetrahydrocannabinol, could be an effective treatment. Despite this,...
Autores principales: | Lavender, Isobel, McCartney, Danielle, Marshall, Nathaniel, Suraev, Anastasia, Irwin, Chris, D'Rozario, Angela L, Gordon, Christopher J, Saini, Bandana, Grunstein, Ronald R, Yee, Brendon, McGregor, Iain, Hoyos, Camilla M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10450062/ https://www.ncbi.nlm.nih.gov/pubmed/37612115 http://dx.doi.org/10.1136/bmjopen-2022-071148 |
Ejemplares similares
-
P066 A randomised, double-blind, placebo-controlled, single-dose, crossover, pilot study investigating the effects of cannabinol (CBN) 30 mg and 300 mg on sleep architecture and next-day function in insomnia disorder
por: Lavender, I, et al.
Publicado: (2022) -
O006 Acute effects of combined cannabidiol (CBD) and ∆9-tetrahydrocannabinol (THC) in insomnia disorder: A randomised, placebo-controlled trial using high-density EEG
por: Suraev, A, et al.
Publicado: (2022) -
Cannabidiol (CBD) and Δ(9)-tetrahydrocannabinol (THC) for chronic insomnia disorder (‘CANSLEEP’ trial): protocol for a randomised, placebo-controlled, double-blinded, proof-of-concept trial
por: Suraev, Anastasia, et al.
Publicado: (2020) -
Cannabinoid receptor 2 (Cb2r) mediates cannabinol (CBN) induced developmental defects in zebrafish
por: Amin, Md Ruhul, et al.
Publicado: (2022) -
Orally administered cannabidiol does not produce false‐positive tests for Δ(9)‐tetrahydrocannabinol on the Securetec DrugWipe® 5S or Dräger DrugTest® 5000
por: McCartney, Danielle, et al.
Publicado: (2021)